A5009268823- SARS-CoV-2 and COVID-19 Research
- Vaccine Coverage and Hesitancy
- HIV/AIDS Research and Interventions
- COVID-19 Clinical Research Studies
- Hepatitis B Virus Studies
- HIV, Drug Use, Sexual Risk
- Cervical Cancer and HPV Research
- Viral gastroenteritis research and epidemiology
- HIV Research and Treatment
- HIV-related health complications and treatments
- HIV/AIDS drug development and treatment
- Pneumonia and Respiratory Infections
- Influenza Virus Research Studies
- Global Maternal and Child Health
- Viral Infections and Immunology Research
- Bacterial Infections and Vaccines
- Pneumocystis jirovecii pneumonia detection and treatment
- Malaria Research and Control
- Long-Term Effects of COVID-19
- Intramuscular injections and effects
- Genital Health and Disease
- Respiratory viral infections research
- Hepatitis Viruses Studies and Epidemiology
- Patient-Provider Communication in Healthcare
- Medication Adherence and Compliance
Moderna Therapeutics (United States)
2022-2025
Research Square (United States)
2023
ViiV Healthcare (United Kingdom)
2019-2022
VA NY Harbor Healthcare System
2021
ViiV Healthcare (Spain)
2020
Pharmerit (United States)
2020
GlaxoSmithKline (Belgium)
2015-2019
Université Laval
2007-2013
Centre hospitalier universitaire de Québec
2007-2013
Hôpital du Saint-Sacrement
2013
The phase 3 trial of the RTS,S/AS01 malaria vaccine candidate showed modest efficacy against Plasmodium falciparum malaria, but was not powered to assess mortality endpoints. Impact projections and cost-effectiveness estimates for longer timeframes than follow-up across a range settings are needed inform policy recommendations. We aimed public health impact routine use in African settings.We compared four transmission models their predictions impact. used data 32 months or parameterise...
Bivalent and quadrivalent human papillomavirus (HPV) vaccines are now licensed in several countries. Furthermore, clinical trials examining the efficacy of a nonavalent vaccine underway. We aimed to compare potential population-level effectiveness bivalent, quadrivalent, candidate HPV vaccines. developed an individual-based, transmission-dynamic model infection disease population stratified by age, gender, sexual activity, screening behavior. The was calibrated highly behavior, epidemiology,...
'Undetectable equals Untransmittable' (U=U) is an empowering message that may enable people living with HIV (PLHIV) to reach and maintain undetectability. We estimated the percentage of PLHIV who ever discussed U=U their main care provider, measured associations health-related outcomes. Secondarily, we evaluated whether impact varied between those heard it from healthcare provider (HCP) vs elsewhere.Data were 25-country 2019 Positive Perspectives Survey on treatment (n=2389). classified as...
Our aim was to examine the potential incremental impact of vaccinating boys against human papillomavirus (HPV) on vaccine-type infection in females and males, using an individual-based HPV transmission-dynamic model. Under base assumptions (vaccine efficacy = 99%, duration protection 20 years, coverage 70%), 12-year-old boys, addition girls, resulted reduction HPV-16/18 (HPV-6/11) incidence over 70 years 16% (3%) 23% (4%) males. The benefit decreased with improved vaccination girls. Given...
The emergence of Omicron variants coincided with declining vaccine-induced protection against SARS-CoV-2. Two bivalent mRNA vaccines, mRNA-1273.222 (Moderna) and BNT162b2 Bivalent (Pfizer-BioNTech), were developed to provide greater the predominate circulating by including that encodes both ancestral (original) strain BA.4/BA.5. We estimated their relative vaccine effectiveness (rVE) in preventing COVID-19-related outcomes US using a nationwide dataset linking primary care electronic health...
The mRNA vaccines mRNA-1273 and BNT162b2 demonstrated high efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in phase 3 clinical trials, including among older adults. To inform disease 2019 (COVID-19) vaccine selection, this systematic literature review (SLR) meta-analysis assessed the comparative effectiveness of versus We systematically searched for relevant studies reporting COVID-19 outcomes with adults aged ≥ 50 years by first cross-checking...
To compare the real-world effectiveness of a third dose mRNA-1273 versus BNT162b2 against breakthrough COVID-19 hospitalizations among adults aged ≥ 65 years who completed primary series an mRNA-based vaccine (regardless which was received). This observational comparative (VE) study conducted using administrative claims data from US HealthVerity database (September 22, 2021, to August 31, 2022). A assessed for preventing and medically attended years. Inverse probability treatment weighting...
Abstract To assess challenges with daily oral antiretroviral therapy (ART), we analyzed data for 2389 participants in the 2019 Positive Perspectives survey of people living HIV 25 countries. ART-related reported included difficulty swallowing pills (33.1% [790/2389]); stress from dosing routine (33.3% [795/2389]); bad memories intake medication (35.1%[839/2389]), and concern “that having to take every day means a greater chance revealing my status others” (37.9% [906/2389]). Individuals who...
Modern antiretroviral therapy (ART) has improved the lives of people living with HIV (PLHIV) but currently requires daily adherence. We assessed prevalence and correlates suboptimal adherence, measured associations self-reported health outcomes. Data were from web-based surveys confirmed HIV+ adults on treatment within 25 countries during 2019 (n = 2389). Suboptimal adherence was a report ≥1 reason for missing ART ≥5 times past month. Multivariable logistic regression examined between...
Aims To assess the potential clinical impact and cost-effectiveness of COVID-19 mRNA vaccines updated for fall 2023 in adults ≥18 years over a 1-year analytic time horizon (September 2023-August 2024).
Abstract Background Few head-to-head comparisons have been performed on the real-world effectiveness of coronavirus disease 2019 (COVID-19) booster vaccines. We evaluated relative (rVE) a primary series mRNA-1273 vs BNT162b2 and Ad26.COV2.S homologous mRNA against any medically attended, outpatient, hospitalized COVID-19. Methods A data set linking care electronic medical records with claims was used for this retrospective cohort study US patients age ≥18 years vaccinated between February...
Objectives A novel long-acting regimen (LAR) of cabotegravir and rilpivirine for HIV treatment requires dosing every 2 months instead daily. We assessed what proportion people living with physicians would be interested in trying offering LAR respectively why. Methods 688 on treatment, 120 completed web-based surveys Germany, Italy, the UK France during 2019. Balanced description a hypothetical regarding efficacy, administration possible side effects were provided. The injections assumed to...
Recent data have shown elevated infection rates in several subpopulations at risk of SARS-CoV-2 and COVID-19, including immunocompromised (IC) individuals. Previous research suggests that IC persons reduced risks hospitalization medically attended COVID-19 with two doses mRNA-1273 (SpikeVax; Moderna) compared to BNT162b2 (Comirnaty; Pfizer/BioNTech). The main objective this retrospective cohort study was compare real-world effectiveness third versus multiple time points on occurrence among...
<h3>Objectives</h3> In 2010, the 13-valent pneumococcal conjugate vaccine (PCV-13) replaced 7-valent (introduced in 2006) for vaccination against invasive diseases (IPDs), pneumonia and acute otitis media (AOM) UK. Using recent evidence on impact of PCVs epidemiological changes UK, we performed a cost-effectiveness analysis (CEA) to compare non-typeable <i>Haemophilus influenzae</i> protein D (PHiD-CV) with PCV-13 ongoing national programme. <h3>Design</h3> CEA was based published Markov...
Head-to-head studies comparing COVID-19 mRNA vaccine effectiveness in immunocompromised individuals, who are vulnerable to severe disease lacking, as large sample sizes required make meaningful inferences. This observational comparative study was conducted closed administrative claims data from the US HealthVerity database (December 11, 2020-January 10, 2022, before omicron). A 2-dose mRNA-1273 versus BNT162b2 regimen assessed for preventing medically-attended breakthrough diagnosis and...
To assess the potential clinical impact and cost-effectiveness of coronavirus disease 2019 (COVID-19) mRNA vaccines updated for Autumn 2023 in adults aged ≥60 years high-risk persons 30-59 Germany over a 1-year analytic time horizon (September 2023-August 2024).A compartmental Susceptible-Exposed-Infected-Recovered model was adapted to German market. Numbers symptomatic infections, number COVID-19 related hospitalizations deaths, costs, quality-adjusted life-years (QALYs) gained were...